 MRD or measurable residual disease stands for those cells which are capable of resisting treatment. The gold standard method to measure MRD is flow cytometry and the preferred sample is bone marrow, since the tumor originates in this sample. Bone marrow is the preferred sample to perform MRD, but to obtain this sample we have to perform our invasive procedure which is bone marrow aspirate and we aim to perform MRD assessment in peripheral blood as it is minimally invasive for a patient. So we developed three new technologies that are glomside, blood flow and mass spectrometry. We see that all these three technologies are capable of detecting MRD in peripheral blood with a high sensitivity. As I said, this is very important for patients because with these technologies we are capable of detecting MRD in peripheral blood and all these three techniques are minimally invasive for them. You should take a deep look into Dr. Noremi Puig has published this year, as since she showed the results from her technology of mass spectrometry in a patient's role in the GMC SAR clinical trial.